“Advancing Hyperbaric Medicine
Globally in the 21st Century ”
August 10-12, 2018
Hyatt Regency Aurora-Denver Conference Center
Denver, Colorado

Paul G. Harch, M.D.
Clinical Professor,
Director of Hyperbaric Medicine,
LSU Health Sciences Center,
New Orleans, LA
Major shareholder, Harch Hyperbarics, Inc.

 58 year old male. Decline in work & memory 8 years before HBOT.
 Alzheimer’s diagnosis 5½ years before HBOT; started on Aricept.
 Continued decline over next 3 years.

 Failure Neotrophin and Exelon
 Begins CPAP 1/01 for 10 year history of sleep apnea. Wife notes

improvement in cognition & behavior.
 89 HBOT treatments in blocks: 5/1/01-9/14/01:
Progressive slow improvement in cognition/behavior.
Generalized improvement in memory scores.
Symptomatically better.
Patient taken off Exelon subsequently due to side effects.
Periodic HBOT in small doses. Transient improvement in affect.
Slow deterioration cognitively.
Re-institution of Exelon and additional medications.
Harch PG. Townsend Letter, April, 2018:417:30-34

5/1/2001: pre-HBOT

Harch PG. Townsend Letter, April, 2018:417:30-34

5/2/2001: post-1 HBOT

Harch PG. Townsend Letter, April, 2018:417:30-34

8/6/2001: post-40 HBOTs

Harch PG. Townsend Letter, April, 2018:417:30-34

9/14/2001: post-80 HBOTs

Harch PG. Townsend Letter, April, 2018:417:30-34

WHAT
IS
HYPERBARIC
OXYGEN
THERAPY?

Hyperbaric Oxygen Therapy is the
use of increased…pressure and
increased oxygen… as DRUGS to
treat pathophysiologic processes
of diseases.1
1. HBO Therapy in Global Cerebral Ischemia/Anoxia and Coma. Chapter 20.
Textbook of Hyperbaric Med., 6th Edition, K.K. Jain (Ed.), 2017.

“A Re-appraisal”
The basis of HBOT:
The Physiology and Biology of
Intermittent Hyperoxia
and Hyperbaric Pressure

A single HBOT:
8,101 genes turned on or turned off.
Turned on Genes:
Growth and Repair Genes,
Anti-inflammatory Genes.
Turned off genes:
Inflammatory Genes
Cell death Genes

What
is
Neurodegeneration?

Neurodegeneration corresponds to any pathological condition
primarily affecting neurons.
Neurodegenerative diseases represent a large group of neurological
disorders with heterogeneous clinical and pathological expressions
affecting specific subsets of neurons in specific functional anatomic
systems; they arise for unknown reasons and progress in a relentless
manner. (A disease of neurons).
Does not include those diseases with neuronal death due to known
causes such as hypoxia, poison, metabolic defects, or infections.

????
Przedborski S. J Clin Invest, 2003;111(1):3-10

Hundreds of different neurodegenerative
disorders, the more common of which
are:
AD, PD, HD, ALS, CTE, Lewy Body Dementia, Prion
disease, Motor Neuron Disease,Spinocerebellar ataxia,
Spinal muscular atrophy, cortico-bg degen., FT dementia,
others.
By 2040 WHO estimates that neurodegenerative diseases
will be the second leading cause of death after
cardiovascular disease in developed countries. 1
Katharine Gammon. Neurodegenerative Disease: Brain Windfall. Nature, 2015:515:299 -300.

Biology:
Apoptosis, oxidative stress, mitochondrial
dysfunction. 1,2
Persistent inf lammation and oxidative stress are crucial
factors of ongoing cell damage. 3
Essentially, Neurodegenerative Diseases are partially
characterized by persistent wounding.
Przedborski S. J Clin Invest, 2003;111(1):3-10
2.
Jomova K. Mol Cell Biochem, 2010;345:91-104.
3. Miller E. Frontiers in Bioscience, Elite, 2017;9:214 -234.
1.

Biology: Reminder
Wounding in the body and central nervous system can
occur by any number of different insults:
(ischemia, hypoxia, toxin, mechanical, electrical, etc.)
all of which generate the dominant
SECONDARY INJURY
(reperfusion injury, inf lammation, edema, ischemia,
hypoxia)

Etiology:
With few exceptions, the causes of NDD are essentially unknown. Even when
identified, the mechanisms…remain, at best, speculative:
Genetic factors: 10% of PD, AD, and ALS are unequivocally familial. 1
For “sporadic” NDD cases, the vast majority of NDD patients, genetic contribution is
minimal. Toxic environmental factors may be the prime suspects, but sporadic cases
may result from a combination of genetic and environmental causes. 1
EXAMPLE: Inhaled particulate matter may significantly contribute to
neurodegenerative disease through neurotoxic effects (Inf lammation, ROS/oxidative
stress, disturbance of protein homeostasis/neurotransmitters) 1
Przedborski S. J Clin Invest, 2003;111(1):3-10
Wang Y. J Applied Toxicology, 2017; (wileyononlinelibrary.com) DOI
10.1002/jat.3451
1.

2.

Treatment:
For the most part, none.
Symptom modulation.
Minimizing oxidative stress.
Antioxidant and redox therapies: Vitamin C, Vitamin E, glutathione,
Lipoic acid, Flavenoids (catechins-green tea, curcumin), ginkgo biloba,
Coenzyme Q 10 , selenium, Omega-3 fatty acids, melatonin, cannabinoids,
physical exercise. 1,2
Jomova K. Mol Cell Biochem, 2010;345:91-104.
2. Miller E. Frontiers in Bioscience, Elite, 2017;9:214 -234.
1.

Treatment:

Hyperbaric oxygen
therapy?

Treatment:
HBOT Paradox:
NDD is caused?/propagated by oxidative stress.
HBOT causes oxidative stress.
Oxidative stress is necessary for the beneficial effects of HBOT. 1
Too much oxidative stress is harmful.
Yet, the net effect of HBOT is reduction of oxidative stress and
inf lammation.

Solution:
Achieving the right amount of oxidative stress through proper
dosing of HBOT
1. Thom, SR, et al.

J Neurobiol, 2002;51:85-100.

2. Poff A, et al. Compr Physiol, 2017;7:213-234.

 The benefits of HBOT are in the proper dosing of oxidative stress

(Harch, 1998).
 Joseph Priestly, 1774: “Though pure dephlogisticated air
(oxygen) might be useful as a medicine, it might not be so proper
for us in the usual healthy state of the body: for as a candle burns
out much faster in dephlogisticated than in common air, so we
might, as may be said, live out too fast and the animal powers be
too soon exhausted in this pure kind of air.”

Remember:
HBOT Gene Effects:

Godman, et al: Anti-inf lammatory genes upregulated,
pro-inf lammatory and apoptotic genes down-regulated
2. Kendall, et al: Inf lammatory and apoptotic genes downregulated.
3. Chen, et al: Neuro-protective and anti-oxidant genes upregulated.
1.

Remember:
Multiple studies of HBOT effects on inf lammation, oxidative
stress, and apoptosis in acute global ischemia/anoxia and
coma. 1
Chronic study:
HBOT effects on degenerative human intervertebral disc cells:
2.5 ATA/120 mins. qod x 3.
HBOT suppressed inf lammatory signaling and mitochondrial
apoptotic pathways. 2
1.

Harch PG. Chapter 20, Textbook of Hyperbaric Medicine, ed. K.K. Jain. 2017.
2. Niu C-C, et al. J Orthop Res, 2013;31:204-209.

HBOT Effects on Mitochondrial Function
(A primary biological dysfunction in NDG Dis):
1. Daily hyperbaric oxygen therapy for life improves mitochondrial function
and delays onset of motor disease in Wobbler mice (ALS model). Dave
KR, et al. Neuroscience, 2003;120:113-120. 2 ATA/60 minutes/d x 30.
2. Oxygen-Induced Mitochondrial Biogenesis in the Rat Hippocampus.
Gutsaeva DR, et al. Neuroscience, 2006;137:493-504. 3 or 5 ATA/45
minutes TDT.
3. Endurance performance is enhanced by intermittent hyperbaric exposure
via up-regulation of proteins involved in mitochondrial biogenesis in mice.
Suzuki J. Physiol Rep. 2017;5(15): e13349,
https://doi.org/10.14814/phy2.13349. 1.3 ATA air/60 minutes TDT, qd,
6d/week, x 24.

 Definition: Dementia is the loss of

cognitive functioning—thinking,
remembering, and reasoning—and
behavioral abilities to such an extent
that it interferes with a person's daily
life and activities.1
 Types: Alzheimer’s (60-70%), Vascular
(25%).2
 1. https://www.cdc.gov/chronicdisease/resources/publications/aag/alzheimers.

Htm
 2. Perng C-H. Psychopharmacology, 2018;235:1571-1580.

 Literature Review: HBOT in Vascular dementia

9 human studies on vascular dementia, all in inaccessible
Chinese journals.
Multiple case reports of HBOT in post-CO dementia.
 Cochrane Review, 2012 (Xiao Y, et al. Cochrane Database Syst Rev,
2012;7:Art. No.: CD009425.
 Single article: Wang SP, et al. Chinese Journal of Physical Med & Rehab,







2009;31(7):478-80.
RCT, 64 patients, vascular dementia.
Donepezil, 5mg qd +/- HBOT: 2 ATA (97% O2)/60 qd x 24 consecutive days,
6d rest, x 3 or 72 HBOTs
Measure: Mini Mental Status and Hasegawa’s Dementia Rating Scale
Results: Significant improvement both measures in HBOT group vs.
Controls (6.2 vs. 3.2 points on MMSE and 7.2 vs. 3.7 points on Hasegawa)
Cochrane conclusion: Insufficient evidence to support HBOT as an effective
treatment for patients with vascular dementia.

1. Xiao Y. Cochrane Database of Systematic Reviews, 2012;7:Art. No.: CD009425.
www.cochranelibrary.com

 Literature Review: HBOT in Dementia
 Studies with positive results:

 Edwards AE. J Am Geriat Soc, 1974;22:376-379.
 Boyle E. Proc. 5th Int HBO Conf, W.G. Trapp (Eds.), Simon Fraser Univ., Canada,









1974; pp. 432-438.
Jacobs EA. J Geriat Psychiatr., 1972;5:107-136.
Jacobs EA. NEJM, 1969;281:753-57.
Jacobs EA. Current Psychiatric Therapy, Vol. II, H Masserman (Ed.), Grune and
Stratton, Phila, 1971: pp. 100-106.
Jacobs EA. Proc. 5th Int HBO Conf., WG Trapp (Eds.), Simon Fraser University,
Canada,;1974; pp. 439-445.
Ben-Yishay Y. NY State J Med, 1973;73:2877-2880.
Ben-Yishay Y. Proc. 5th Int HBO Conf, WG Trapp (Eds.), Simon Fraser University,
Canada, 1974; pp. 424-431.
Ben-Yishay Y. NY State J Med, 1978;78:914-919.

Schmitz GF. Evaluation of HBOT for Senility. HBO Review, 1981;2(4):231-250.

 Literature Review: HBOT in Dementia
 Studies with negative results:
 Thompson LW. J Gerontol, 1976;31:23-28.
 Raskin, A. Arch Gen Psychiatry, 1978;35:50-56.
 Goldfard AI. J Gerontol, 27:212-217.
 Conclusions:
 “At the present time there is no basis for claiming that

hyperbaric oxygen is beneficial in reversing senility or any other
central nervous system deficit which occurs in the aged. There
is a lack of scientifically sound data on this topic.”
Schmitz GF. Evaluation of HBOT for Senility. HBO Review, 1981;2(4):231-250.

 Literature Review: HOWEVER!
 Meta-analysis on treatment of dementia
 Review of literature 2000-2016
 235 studies, 44,854 patients, vascular, Alzheimer’s dementia,

mild cognitive impairment, and mixed.
 Reviewed 5 types of treatments:
 Antipsychotic drugs and cognitive enhancers
 Symptomatic treatment drugs for Vascular Dementia (piracetam,

nimodipine, aniracetam, flunarizine, vinpocetine, HBOT,
oxiracetam, or EGB761).
 Behavioral therapy (exercise, music, reminiscence, rehab, cog, PT
 Adjunctive therapy (Chinese herbal and medicine, decoctions
 Other alternative treatments: scalp acupuncture, Premarin, statin,
butylphthalide soft capsules, donepezil, huperzine A, and lithium
Perng C-H. Psychopharmacology, 2018;235:1571-80.

 Literature Review:
 Results:
 Treatment 1 lowest efficacy.
 Treatment efficacy increases with publication year and

decreases with age of the patient.
 Treatment 2 and Treatment 4 had the highest efficacy for
treating cognitive dysfunction
 Vascular Dementia patients had the greatest cognitive
improvement.
 Treatment 2 and Treatment 5 had the highest efficacy vs.
other treatments (p=.010 and .001) in relatively young
patients with vascular dementia.
 Alternative therapies are effective in the treatment of
dementia.
Perng C-H. Psychopharmacology, 2018;235:1571-80.

 Lecturer’s personal experience:
 First case in 1995.
 75 y.o. female, urosepsis/shock in 1992, coma x one week, progressive
decline in mental function noted by treating physicians, disputed by
husband.
 Repetitive falls 1-3/1994 without TBI, RSD LUE due to injury.
 24h nursing care.
 9/1994: fall, subdural hematoma, accelerated decline in mental status.
 10/1995: evaluation in New Orleans
 Incontinence, hostility, blind right eye, wheelchair-bound, depressed, disorient,








blank stare.
MRI: 8/95: atrophy + multiple small CVAs (right caudate, corona radiata, internal
capsule, left occiput).
Neuropsych testing: “failed.”
PMH: RA, DM.
Folstein: 11, after 3rd HBOT.
SPECT, dive, SPECT.
38 HBOTs, 1.5/60, 11-12/1995, bright, alert, increased ADL’s, Folstein 13

 Lecturer’s personal experience:
 First case in 1995.
 30 HBOTs 1-3/1996, total 68 HBOTs. peak improvement at 19, total 57,








mild deterioration afterward.
Clinically improved: conversational, not combative, feeding self
independently, incontinence decreased, diaper frequently dry and
signals that needs to use bathroom, watching TV and reacting
appropriately to events/news.
PEx: bright alert, follows commands, gets out of chair unassisted,
unassisted gait.
Husband made non-profit donation that funded TBI animal study:
human protocol of HBOT in chronic TBI, became first and only
improvement of chronic animal brain injury in history of science.
Repeat SPECT after 57th HBOT.
Second case (vide supra): 2001, presented to congress 2002.

 Four months: nightly confusion, memory loss, paranoia, and inappropriate








behavior. Removal from grandchildren’s home.
Three hospital admissions for GI bleed in three months.
Emergency department visit for dementia and dehydration.
Deterioration in flight to New Orleans with emergent hospital admission.
6th hospital admission: upon arrival inNew Orleans, Dx: dementia and SOB.
PMH: Long history of alcohol and tobacco abuse with several TBI’s and CO
exposure (Normal aging?).
PEx: Cachectic, SOB elderly man. Folstein: 15/30. 40 HBOT’s:






Generalized cognitive improvement
Increased energy
Decreased SOB and confusion
Improved sleep, weight gain.
Followup: Semi-independent living. Some regression 3 months post HBOT.

7/22/2003

7/29/2003

9/15/2003

 Lecturer’s personal experience:
 Subsequent ~70+ cases of cognitive decline or dementia
 All causes: small vessel ischemic disease, postsurgical/anesthesia, trauma, stroke, toxins,
Alzheimer’s, multiple cause/premature aging.
 1.15-1.5 ATA/60-90 minutes, qd, 40 treatments, or
more.
 Functional imaging (SPECT), MMSE, and clinical
outcomes.
 Best results in small vessel ischemic disease, TBI,
post-anesthesia, post-chemo, Alzheimer’s.
 Least positive in cortico-basal ganglia degeneration,
fronto-temporal dementia (Pick’s), Parkinson’s
(motor findings), multiple systems atrophy.

 Case Report, Literature Review:
 77 y.o. male, 4.5 y post knee replacement.
 Immediate deterioration post surgery.
 Demented, unresponsive to pharmacotherapy.
 HBOT, 1.75 ATA/60 minutes x 40. Post 11th HBOT
weekly perispinal Enbrel (etanercept) for 5 months.
 At the 5 month mark, patient was able to care for
himself, go on walks by himself, had return of his
personality, normal sleep cycle, interact with others.
Best S, Pavel DG. J Medical Case Reports, 2017;11:105, DOI 10.1186/s13256-0171259-6.

 Case Report:
 SPECT brain imaging at 5 month mark:

Best S, Pavel DG. J Medical Case Reports, 2017;11:105, DOI 10.1186/s13256-017-1259-6.

 Alzheimer’s Disease Definition: An

irreversible, progressive brain disorder
that slowly destroys memory and
thinking skills, and eventually the
ability to carry out the simplest
tasks…the most common cause of
dementia.1 Closely connected with
deposition of amyloid beta plaques and
neurofibrillary tangles in brain tissue.2

1. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet.
2. Miller E. Frontiers in Bioscience, Elite, 2017;9:214-234.

 Alzheimer’s Disease Statistics:
 Affects 30 million people worldwide,1 5.4 million in











U.S.2 Numbers double every 20 y.
Comprises 60-70% of all dementia.3
Costs: $818 billion/y worldwide (1% of global GDP),1
$259 billion/y U.S.2
Treatment: largely pharmacotherapy.
Of 244 drugs tested from 2002-2012, only one with
FDA approval (Onyango, 2018).4
No therapy has effectively halted disease
progression.4

https://www.alz.co.uk/research/statistics
https://www.cdc.gov/chronicdisease/resources/publications/aag/alzheimers.htm
http://www.who.int/mediacentre/factsheets/fs362/en/
Frozza RL. Front Neurosci, 2018;12:37.

 Single case Report (See above: Harch, PG, congressional testimony

2002 and Townsend Letter 4/2018).
 Recent animal study:
 Shapira:

 Old mice: normal and transgenic Alzheimer’s mice.
 Behavioral, histological, and biochemical analyses pre

and 24-48h post HBOT or the last behavioral task.
 HBOT: 2 ATA/60 minutes qd x 14.
 Results: HBOT reduced inflammation (decreased
astrogliosis, microgliosis, IL-1Beta, TNF alpha, and
increased scavenger receptor A, arginase 1, IL-4 and 10),
reduced hypoxia,k amyloid burden, and tau
phosphorylation. Ameliorated behavioral deficits.
1.

Shapira R. Neurobiology of Aging, 2018;62:105-119.

 Lecturer’s personal experience:
 11 cases since 2001
 Diagnosis by various neurologists

 Nearly all on dementia drugs
 SPECT brain imaging pre/post HBOT on majority
 HBOT at 1.15-1.5 ATA/60 minutes x 40 (most) or 80.
 8 of 11 with clinical and Mini Mental Status improvement.
 PET imaging pre/post on most recent case:
 Clinical symptomatic improvement
 Improvement in FDG PET: average 17% global increase.

 Subsequent intermittent treatment over 18 months with maintenance

of Folstein Mini-Mental Status Score
 Simultaneous use and disuse of Alzheimer’s drugs.

 Parkinson's disease (PD) belongs to a group of conditions called

motor system disorders, which are the result of the loss of
dopamine-producing brain cells in substantia nigra. The four
primary symptoms of PD are tremor, or trembling in hands,
arms, legs, jaw, and face; rigidity, or stiffness of the limbs and
trunk; bradykinesia, or slowness of movement; and postural
instability, or impaired balance and coordination.1

 Pathological characterized as intracellular deposition of alpha-

synuclein (AS) in Lewy Bodies; a soluble protein w/ prion-like
properties (spreading).2

 Essentially, is a multi-system disorder: CNS & PNS.2
http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease.htm
2. Borghammer P. Movement Disorders, 2017; Aug 26. doi: 10.1002/mds.27138. [Epub ahead of print]
1.

 However, AS affects an array of different

neurons, including nigral, cortical, enteric,
and cardiac neurons.1
 Alpha synuclein deposition in other areas
of the brain outside the substantia nigra.
may account for the diverse Sx in PD.2
 Release of AS from neurons and other
evidence points to possible inflammation
involvement in the pathogenesis of PD.1
1. Engelender S. Trends in Neurosciences, 2017;40(1):4-14.

2. Adler CH. Movement Disorders, 2016;31(8):1114-9.

https://en.wiki
pedia.org/wiki/
Basal_ganglia

Anatomy of Parkinson’s
Disease

Coronal slices of human brain showing the basal ganglia. White matter is shown in dark
gray, gray matter is shown in light gray.
Anterior: striatum, globus pallidus (GPe and GPi)
Posterior: subthalamic nucleus (STN), substantia nigra(SN)

Connectivity
of the basal
ganglia
https://en.wikipe
dia.org/wiki/Bas
al_ganglia

Connectivity of the basal ganglia as revealed
by diffusion spectrum imaging based on
thirty subjects from the Human Connectome
Project. Direct, indirect and hyperdirect
pathways are visualized in different colors
(see legend). Subcortical structures are
rendered based on the Harvard-Oxford
subcortical thalamus as well as the Basal
Ganglia atlas (other structures). Rendering
was generated using TrackVis software.

 Different anatomical areas affected by

Parkinson’s are subserved by different
neurotransmitter systems.
 The primary neurotransmitter is
dopamine.
 However, there are multiple others.

Dopamine
Pathways
In the
brain

http://en.wikipe
dia.org/wiki/Ans
a_lenticularis
The image shows dopaminergic pathways of the human brain in normal condition (left)
and Parkinsons Disease (right). Red Arrows indicate suppression of the target, blue arrows
indicate stimulation of target structure. (Ansa lenticularis visible but not labeled, as red
line from GPi to THA.)

Glutamine, GAB A,
and Dopamine Pathways in the basal
ganglia
https://en.wikipe
dia.org/wiki/Bas
al_ganglia
Diagram shows two coronal slices that
have been superimposed to include the
involved basal ganglia structures. Green
arrows (+) refer to
excitatory glutamatergic pathways,
red arrows (–) refer to
inhibitory GABAergic pathways
and turquoise arrows refer
to dopaminergic pathways that are
excitatory on the direct pathway and
inhibitory on the indirect pathway.

 Heredity-10-15%, remaining 85% are sporadic, all causes:
 Drugs: MPTP (methyl phenyl tetrahydropyridine), designer drugs







(Los Angeles outbreak in the 1980s).
CNS infections
Heavy metals (Manganese, others)
Toxins: CO, pesticides, herbicides, Agent Orange, other
Trauma (Muhammed Ali)
Ischemia/hypoxia/vascular
Rural living, well water contamination

Parkinson’s Disease Foundation:http://www.pdf.org/causes#enviro
https://nwpf.org/stay-informed/news/2010/12/toxic-causes-of-parkinsons-disease/

 64 patients, 37-78 years old, 29 men, 35 women
 Duration of illness: 1-15 years, at least 5 yrs. in most

patients
 Causes:
 Atherosclerosis: 49 patients
 Atherosclerosis + high blood pressure: 6 patients
 Encephalitis: 8 patients
 Closed head injury: 1
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2

 Treatment: HBOT @ 1.3-2.0 ATA/40-60 minutes for 8-12 Rxs.
 “Nootropic medications and preparations involving the

microcirculation” in all. 37 continued their medications.
 Results:
 1 or two HBOTs caused improvement in general state of feeling in

all patients.
 Perceptible shifts in neurological status were identified (4-6 Rxs)
 1/3rd of patients: improvement in mood, cognition, decreased tone
after 2-3 HBOTs.
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2

 Results:
 Akinetic-rigid had greater response than other

forms (vascular etiology)
 Good results: 18 patients, remission in 3 of these.
 Satisfactory results: 26 patients.
 Insignificant results: 11 patients.
 Tremulous patients responded to higher dose
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2

 Results:
 No change: 5 patients, however, during HBO and for

1-3h afterwards, a decrease in the “frozen character
and severity of tremor” were observed.
 Discontinued treatment: 4 patients (claustrophobia
and hypertensive crises)
 Results better in vascular Parkinson’s than in the
encephalitic form
 36 patients maintained improvement for upto six
months. The HBOT course was repeated two
times/year to stabilize the condition.
Neretin VY, et al. Neuroscience and Behavioral Phys 1990;20(6):490-2

 15 patients, 46-85 years old (avg. 65.5), 8 men, 7

women
 Duration of illness: 6-25 years
 Causes:
 Idiopathic: 7 patients
 Vasculopathic: 4 patients
 Encephalitis: 3 patients
 Other: 1
Boromei A. Procs. of 12th Int. Congr. on Hyper. Med. Best Publishing Co
1998

 HBOT: 2 protocols
 Decompensated or complicated, non-vascular: 15

treatments + 5 treatments q 3 months: 1.9 ATA/80 w 10
mins./2mins. cycles of O2/air.
 Complicated, vascular causes: 25 treatments + 5
treatments q 3 months: 2.5 ATA/90 w 10 mins./2 mins.
O2/air.
 Outcomes measured with Webster Rating Scale (motor)

and Crichton Geriatric Behavioural Scale (ADLs and
behaviour).
Boromei A. Procs. of 12th Int. Congr. on Hyper. Med. Best Publishing Co 1998

 Results:
 Significant improvement on both scales
 High correlation of the scores on the two scales after

treatment
 Improvements characterized by improvement in
motor, mood, and overall function.
 Average 9 month outcome.
Boromei A. Procs. of 12th Int. Congr. on Hyper. Med. Best Publishing Co 1998

 45 y.o. man with 1.5 yrs. of progressive tremor,

bradykinesia, accelerating in past 3 months with
depression and anxiety.
 Prescribed anti-Parkinson’s meds in past, ineffective,
refused further meds.
 MRI brain and ultrasound head and neck negative.
 HBOT: 2.0 ATA/80 mins./10 min. air break qd x 30.
 Results:
 After 4 HBOTs: improved sleep quality and duration

(from 2-3h to 5h/nite). Improved mood.
Xu, Jin-Jin. Medicine, 2018;97:9(e0029)..

 At end of HBOT:





Normal sleep time (8-10h)
Weight increased by 10kg.
Tremor and bradykinesia improved significantly.
One month post: persistent gains, no need assistance with ADLs.

Xu, Jin-Jin. Medicine, 2018;97:9(e0029)..

 Lecturer’s Experience: crude recall
 ~10 cases
 HBOT at 1.25-1.5 ATA/60-90 minutes, qd, x 40
 Limited response:
 Minor effect on motor symptoms
 Some improvement on other symptoms of PD: cognition, affect.
 ? Wrong dose or ineffective for this disease.

 Amyotrophic Lateral Sclerosis: a rare group

of neurological diseases that results from
the gradual deterioration and death of
upper and lower motor neurons that are
responsible for controlling voluntary
muscle movement.
 https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-

Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet

 Amyotrophic Lateral Sclerosis:
 Phase I study:
 5 patients
 HBOT: 2 ATA/60 mins., daily, 5d/week, 4 weeks.
 Measure neurological condition serially during 4 wks. of Rx and for

4 wks. post Rx.
 Results:
 4/5 patients: decreased fatigue
 Maximum isometric voluntary contraction of all muscle groups except right hand grip

improved significantly by up to 97%.
 Most improvement occurred during the 4 weeks after treatment.
Steele J. Amotroph Lateral Scler Other Motor Neuron Disord, 2004;5(4):250-4.

 Amyotrophic Lateral Sclerosis:

 Phase II “single-blind (patients)”

controlled study:
 10 patients divided into 2 groups, flip of coin, 1st group HBOT, 2nd

group HBA.
 HBOT: 2 ATA/60 mins., daily, 5d/week, 8weeks, by hood. HBA
group: oscillating pressure to 1.3 ATA/60 mins. by mask.
 Measure neurological condition and muscle strength serially every
4 wks. up to 20 weeks.
Steele J. Amotroph Lateral Sclerosis, 2007;8:274-275.

 Phase II “single-blind (patients)” controlled

study:
 Results:
 “Some patients in both groups did not complete all the treatments and evaluations due to





disease-related problems. (1 dropout in HBOT due to non-related injury).
Data analysis of all HBOT patients and at the 12 week mark for the control group. No 20
week followup because HBOT group did not improve.
Progressive decline in function for HBOT group to 81.5% of baseline muscle function by
week 20.
For Control Group decline to 89% of baseline by week 12.
Improvement in ~20% of muscle groups seen at 8 weeks in both groups.

Conclusion: Didn’t work, don’t recommend
Lecturer: Hard to reconcile these results with Phase I study. Overdose? (20 vs. 40
HBOTs).
Steele J. Amotroph Lateral Sclerosis, 2007;8:274-275.

 Kim Cherry Case:
 63 y.o. male diagnosed with bulbar ALS on 11/22/2011.
 Sx: problems swallowing, breathing, choking weakness,

imbalance.
 Early response to NBO. Then gluten-free diet, supplements,
ozone Rx, HBOT. Progressive improvement. 5/2017 stopped
HBOT and started exercise on oxygen.
 Able to play golf, walk, talk, has good quality of life 6 years
post-diagnosis.
 Keys to success: positive mental state, Higher Power, detox,
diet, oxygen therapy.


http://www.alswinners.com

 What is CTE?
 A progressive neuro- degener-

ation characterized by the widespread deposition of hyperphosphorylated tau (p-tau) as
neurofibrillary tangles triggered by repetitive mild traumatic brain injury.1

 Is a pathological diagnosis.
 Originally described clinically in boxers (“punch drunk”) as

dementia pugulistica.
 Clinically associated with symptoms of irritability, impulsivity,
aggression, depression, short-term memory loss and
heightened suicidality that begins 8-10 years after experiencing
repetitive mTBI.2
1. McKee AC. J Neuropathol Exp Neurol, 2009;68:709-35.
2. Mckee AC. Brain, 2013;136(Pt 1):43-64.

Diffuse Axonal Injury

Diffuse axonal swelling (brown)
http://neuropathology-web.
org/chapter4/chapter4b
Contusions_dai_sbs.html

Axon contraction balls
http://moon.ouhsc.edu/
kfung/JTY1/NeuroSim/
Sim05-B-Diss-4-a.htm

 Amyloid beta (red), Paired

Helical Filaments of microtubule protein tau (brown).
 First 3 rows: Alzheimers
 Last 4 rows: CTE
 Lesions at depths of sulci
and perivascular.

Mckee AC. Brain, 2013;136(Pt 1):43-64.

 Wounds in the Brain:

Mckee AC. Brain, 2013;136(Pt 1):43-64.

Marx Model of Perfusion Gradient Wound

5,5,10,15,20,35,40, 55 mm Hg

 = 10 - 20 mm Hg

During HBO at 2.4 ATA

50, 50, 90, 15, 120 - 350 mm Hg

 = 230 mm Hg

5, 15, 25, 40, 55,

55 MM Hg

 = 10 mm Hg
 = 10 - 15 mm Hg
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HBOT
is a treatment for

WOUNDS
in the body in

ANY LOCATION
and of

ANY DURATION

 CTE: However!
 There is little doubt that some athletes may suffer from long-term

adverse effects from multiple sport-related concussions (SRC).
 A cause and effect relationship between concussions and/or contact
sport participation and CTE (p-tau deposition, that causes the
clinical syndrome) has not yet been demonstrated.
 No compelling empirical evidence to indicate that SRC or
subconcussive impacts are the sole and direct cause of psychiatric
illness, suicide, MCI, or neurodegenerative disease/CTE.
 Must account for genetic, medical, psychiatric, substance abuse, and
biopsychosocial variables.
Solomon G. Develop Neuropsychol, 2018;43(4):279-311

Early case experience
(New Orleans and Slidell, LA)
1. Gratuitous neurological improvement in extremity wound
patients with chronic neurological diagnoses.
2. Divers with subacute cerebral decompression illness.
3. Louisiana boxers: Dementia Pugulistica Study:
a. Community Hospital IRB
b. Funded by The Hirsch Foundation ($20,000) to Keith Van
Meter, M.D. and Sheldon Gottlieb, Ph.D. of the
Baromedical Research Foundation of New Orleans.
c. 3 Boxers evaluated, two treated, one with dementia
(1989).

Dementia Pugulistica Study
Case Presentation
R.D.
55 y.o. male
Boxing 15-32 y.o., 15 years professionally
135 professional bouts, last one 23 years before HBOT
World champion
1 LOC in 1st 100 bouts, 4 LOCs in last 5 fights, last LOC
x 3-5 mins.

Subsequent 10 years casino work with declining ability
(Black Jack…roulette wheel… shuffle cards… fired)
Paranoia begins 2 years after last bout, eventual
hallucinations.
Diagnosis: Paranoid schizophrenia, supervised care by
family, able to dress and feed self.
Meds: Artane 2mg tid, Ativan 2 mg tid, Stelazine 2mg bid,
occasional Percodan, Soma.
PEx: Conversant, suspicious, skulking panther like
movements (basal ganglia injury?)
Slow speech, disoriented, abnormal balance and gait.
Slow speech. Poor short and long-term memory.
Neuropsychological testing: Marked global impairment
with many tests in the 1-2% ile range.

SPECT, pre and post 1 HBOT (1.75 ATA/65):
Marked decrease in blood flow bilateral
temporal lobes (R worse) and less so frontal
lobes and right parietal lobe. Post HBOT
marked increase in flow to the right TL,
normalization of FLs and right PL.
MRI, brain: Moderate central and cortical
atrophy, right occipital WM infarct and area
of porencephaly.

HBOT:
10/1991-3/1992: 1.75 ATA/65 mins. x 1
1.5 ATA/65 mins. x 20
3 week break
1.75 ATA/70 mins. x21 (42
HBOTs)
3 week break
2.0 ATA/70 mins. x 21 (63
HBOTs)
Confusion, decreased memory, imbalance,
shakiness during 1st 15 HBOTs.

HBOT:
Improved Symptoms: 16-20 HBOTs
21-42 HBOTs
43-63 HBOTs
Repeat SPECT hours post:
21st HBOT, at 1.5 ATA
42nd HBOT, at 1.75 ATA
63rd HBOT, at 2.0 ATA
Results SPECT:

Transverse Slices

Repeat PEx: Faster, more fluent speech, less
paranoia, improved mood, energy, gait, balance.
Family impressed with change in persona. Brother
(former boxer) upset that he could not get
treatment for his deficits.
Repeat NP testing: improvement in multiple
domains, but only small improvement in %ile
ranking. Patient was more oriented, knew for the
first time on final testing why he was there, and the
purpose of the testing.










Case Presentation #2
Tom Dempsey, 64 y.o. retired
NFL player (permissions granted).
6 concussions that he can count,
but only remembers 3, none with https://www.detroitathletic.com/ https://en.wikipedia.org/wiki/Tom
_Dempsey#/media/File:Tom_demp
sey.jpg
blog/wpLOC: 1969, 1971, and 1974.
content/uploads/2012/12/tomdempsey.png
Each with confusion, HA, disorientation, played rest of game,
symptoms lasted 1 week.
Retired 1979. By 2008 developed irritability, mood disturbance
with flashes of irrational anger. Significant alcohol intake,
previous chewing tobacco, steroid use once. (Solomon article!)
Entered study on brain imaging of NFL players in 2011 (Dr. Amen).
http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html










Case Presentation
PMH: DM, Meds: supplements, Metformin, Glipizide,
Lisinopril, Pravastatin.
FH: dementia in two aunts manifest in their 50s.
Neuro ROS: snoring (no evidence OSA pattern), dizzy in
heat, poor enunciation, decreased balance, general cognitive
decline, decreased energy level, mood swings, irritability.
PEx: deformities of right hand and foot, positive glabella and
snout, poor tandem gait, bradykinesia.
SPECT: 3-D only—abnormal bilateral TLs, orbital FLs, and
high parietal watershed areas.
Folstein MMSE: 24
http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html

MicroCog Assessment 2011

qEEG TBI Discriminant Analysis 2011

SPECT 3-D Surface Reconstruction 5/23/2011

SPECT Cage View Reconstruction 5/23/2011

Case Presentation: Tom Dempsey
 HBOT: 1.4 ATA/60, qd, x 40, 5-7/2011.
 Re-Eval:
 Mixed result. Early symptomatic improvement. Disappointed








later: pt. was hoping for big improvements.
Started driving again at times.
Mild improvement balance, memory at times, energy level
Could retell his stories better.
PEx: balance worse.
Folstein decreased to 21-22 (off by 1 day on date).

http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html









Case Presentation: Tom Dempsey
In the months following HBOT, improvement.
1/2013, 18 months post HBOT: “clearcut improvement.”
Sustained driving. Getting after-care through Tulane Sports
Medicine Program.
Later 2013, 24 months post HBOT: “nosedived.” Continued
after-care. Wife unable to care for patient. Put in nursing
home. Slow progressive decline.
5/5/2018: in nursing home, total dependence, can’t feed self,
“doesn’t know how to walk.” Jeri-chair. “Doesn’t recognize
anyone. “ Physically healthy.
http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html

Case Presentation: Tom Dempsey
 Conclusion:
 Initial response to HBOT with more noticeable improvement in





months after treatment (Dose implications?).
No further HBOT.
Sustained benefit of HBOT, coupled with additional PT and
stimulation.
Precipitous decline.
Alive, healthy, late stage dementia.

http://www.theadvocate.com/new_orleans/sports/saints/article_57cb7d51-2847-50a2-bf82-e6b6c1577d07.html

Case Presentation #3
Retired NFL linebacker; 46 years old
cc: Wants to preserve brain, scared of appearance of old friends, is
tired, gets punchy after airplane flights.
Played football from 10-37 y.o., professionally for 16 years. Tackled
with head.
22 documented concussions, one with LOC. Remembers “seeing
stars” at least once/game or practice for entire career.
Steroid use throughout professional career, “always on some
anabolic stimulant.” Stimulants every year of professional football.
Transient effects of concussions became permanent with
simultaneous increasing fatigue.
Contacts PGH, M.D. 2000-2001 football season: had been using
HBOT (hardshell and portable) and was “exhausted,” couldn’t finish
season.
Recommendations to use HBOT for recovery and head injuries
instead of performance enhancement.

Case Presentation
Finished 2000-1 and 2001-2 seasons and was symptomatically
improved.
 Traded to another team in 2002. No HBOT. Concussions
accumulate, increasing toll, unable to play due to neuro Sx,
confusion after away game in 2003. Couldn’t travel home.
Extensive workup: NP, MRI. ? Results. Sx improve over time.
Repeat CT, MRI, EEG in 2006 @ U. of Pittsburgh-normal.
Neuro ROS: STM problems, short-temper, irritable, avoids crowds,
commotion, low energy level, decreased smell, taste, generalized
cognitive decline
PMH: testosterone, Arimedex (increases testosterone), vitamins,
apnea in sleep, 500 mg caffeine/day
FH: addiction, Alzheimer’s in mother, two others with Alzheimer’s,
EtOH, depression. (Solomon article!)
PEx: balance and coordination findings.

SPECT, single HBOT at 1.4 ATA/50, repeat SPECT
Improved vision, energy level, thinking clearer, feels better post

single treatment.
35 additional HBOTs, 1.4/50, qd, 5d/week. IV glutathione and
phosphatidyl choline, and NAC pre-HBOT, tiw.
Re-Eval: improved on nearly all symptoms and PEx findings.
Noted by wife and employees.
Repeat SPECT, 4/2013: improved.
One month later, Sx regression. Doing multiple therapies. No PCP
F/U.
One month later, 15 additional HBOTs. Improved. Continued
treatment…..exhaustion, headaches. Stopped HBOT. Rebound.
One month later, restart HBOT, additional 19 HBOTs, improved
until last 10, deterioration.
Evaluation 2 weeks later, overall improvement: focus, memory,
reading, energy level, mood control. PEx: ~same as post 36 HBOTs.
Repeat SPECT, 8/2013: slight deterioration compared to post 36
treatments.

What does a normal
person look like on
brain blood flow
scanning?

Normal 34 year old male: LSU IRB 1998-2001

Purportedly Normal 34 year old male: LSU IRB 1998-2001

Normal 34 year old male: LSU IRB 1998-2001

Purportedly Normal 34 year old male: LSU IRB 1998-2001

Normal 34 year old male: LSU IRB 1998-2001

Purportedly Normal 34 year old male: LSU IRB 1998-2001

2/4/13-2/5/13—Post 1 HBOT

2/4/13-4/18/13—Post 36 HBOTs

2/4/2013

4/18/2013

2/4/13-8/21/13—Post 70 HBOTs

4/18/13-8/21/13—Post 36/70 HBOTs

2/4/13—3-D Surface

2/5/13—3-D Surface

4/18/13—3-D Surface

8/21/13—3-D Surface

Followup:
5/12/2018: Patient remains active
in his multiple businesses, has
sponsorship by a national
corporation, and hosts a radio
show.
? Additional HBOT

 Literature Review: Single publication
 Stoller, Medical Gas Research, 2011;1:17: 1 of 2 cases:
 “In his early 50’s”, retired NFL player.
 mTBI w/LOC Pop Warner football-youth
 Numerous concussions through football career (high school,
University of Colorado).
 2nd ”major” concussion during 1st play in NFL, San Francisco
49ers.
 25-30 smelling salts to finish game.
 2nd season, concussion, headache, multiple evaluations by
team trainer and physician. Pain pills.
 Increasing headaches.

 Stoller, Medical Gas Research, 2011;1:17
 2nd season,
 Hydrocephalus.
 Emergency VP shunt.
 11 subsequent shunt revisions over 9 years.
 19 years later (2009) undergoes 40 HBOTs at 1.5 ATA/60
minutes for ?Sx.
 MicroCog assessment pre/post HBOT (improvement on
5/6 indices).
 SPECT brain imaging pre/post HBOT (improved on
surface 3-D reconstruction).

 Stoller, Medical Gas Research, 2011;1:17

 SPECT surface 3-D pre/post HBOT:

Pre-HBOT

Post-HBOT

 Conclusions:

 CTE is a pathological condition resulting from multiple

traumatic wounds of the brain, possibly in combination with
other insults, that is associated with a multi-domain clinical
condition.
 HBOT is a treatment for wounds in any location and of any
duration
 Limited case experience with HBOT in CTE.
 Encouraging outcomes with HBOT in CTE consistent with
HBOT treatment of other chronic cerebral wounding
conditions, such as persistent post-concussion syndrome.

 58 y.o. Caucasian female with cognitive decline over 8 months

 Extensive workup negative: blood work, MRI, MRA, bubble-







contrast TTE, PVD study, abdominal ultrasound, 24h Holter
monitor, carotid ultrasound.
EEG: diffuse slowing.
APOE: homozygous e3.
Abnormal neuropsychological testing.
Abnormal PET.
PMH:





natural gas exposure/syncope 9 y.o.
Childhood exposure oil refineries, metallurgy plant.
10 year work exposure to mold post Hurricane Katrina
Lifelong hypotension.

 FH: brother with dementia secondary to TBI (concussions, boxing),

drug abuse, ECT.
 PEx: abnormal:
 slight tremor, decreased pinprick bilateral face, instability on deep
knee bend, decreased pinprick in distal 4 extremities, diffuse
hyperreflexia, trouble following directions, tandem gait,
disdiadokinesis, Romberg, finger-to-nose.
 Patient refused all medications except Lexapro, Biotin, Vitamins

B12 and D three weeks pre-HBOT.
 HBOT: forty 1.5 ATA/50 minutes total treatment time, once/day,
5d/week HBOTs in 66d.
 After 21 HBOTS patient reported symptomatic improvement with
increased energy/activity level, mood, ability to draw a correct
clock face, perform activities of daily living, and work crossword
puzzles.

 Neurologist started Exelon patch 9.5 mg for one week:

discontinued by patient.
 At completion of 40 HBOTs patient reported
 increased memory and concentration, not getting lost as

frequently, resolution of anxiety, improved sleep, ability to use
the computer, more good days (5/7) than bad days, better
conversation, less frustration, increased appetite.
 Tremor, deep knee bend, tandem gain, motor speed were
improved.
 Repeat PET one month post HBOT showed global improvement in
brain metabolism.
 Two months post-HBOT patient felt a regression in her

symptoms. Exelon was begun at 9 mg, increased to 12, then
decreased to 9 to GI intolerance.

 After 4 weeks Exelon was discontinued due to no

improvement in symptoms.
 Four months post HBOT patient had repeat NP testing
which showed improvement in some scores, no change in
many, and worsening of many.
 Over the 18 months post NP testing patient has received 61

HBOTs.
 Folstein Mini-Mental status during this time is as follows:
 1/17/17: 22. Oxygen concentrator, 3x/wk x few weeks before this date.





Restart Exelon patch 2/2017.
5/12/17: 23. 70 HBOTs by this date.
8/28/17: 23. Exelon, oxygen concentrator.
2/7/18: 19. 88 HBOTs. Off Exelon x 2d. Start Donepezil, 5 mg/day.
6/21/18: 22. 96 HBOTs.

 Conclusion:
 HBOT generated a diffuse increase in brain

metabolism, including the signature areas responsible
for Alzheimer’s Disease.
 This implies an HBOT effect on more than just acetyl
choline pathways.
 Simultaneously, the patient experienced an
improvement in symptoms and physical exam.
 The HBOT effect was sustained with additional HBOT
and medications.

 Neurodegenerative Disorders have many causes.
 Many of the causes of ND result in wounding of the brain.

 Persistent inflammation is crucial in the pathogenesis of ND.
 HBOT is a reparative treatment for wounds.

HBOT is anti-inflammatory.
 HBOT dosing is a matter of matching the dose of pressure and
oxygen to the pathological targets in the disease.
 The literature on HBOT in ND is not substantial, but sufficient
enough to suggest that HBOT has a place in the treatment of ND,
especially dementia.

